The domestic entry of the biosimilar of Lantus will create a powerful diabetic lineup for BI-Lilly

Boehringer Ingelheim and Lilly (hereinafter referring to BI-Lilly)are about to dominate the diabetic treatment market.

They are preparing entry of the biosimilar product of the Sanofi’s basal insulin release ‘Lantus (insulin glargine)’. The current manufacturer of the product, Lilly, is getting ready to conduct a Phase 3 clinical trial for the insulin analog ‘LY2963016’ under an approval of th...